Aslan Fred's Form 4 filing
Artiva Biotherapeutics, Inc. (ARTV) · filed May 19, 2026
- Accession no.
- 0001193125-26-231506
- Filed
- May 19, 2026
- Trade date
- May 19, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $244.3K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Aslan FredCIK 0001909362 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 19, 2026 | Common Stock | SSaleDisposed | −27,116 | $9.01F2 | −$244,315.16 | 1,535,082 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.